NASDAQ: DVAXDynavax Technologies Corp Stock
$9.67+0.16 (+1.68%)
Updated May 16, 2025
DVAX Price
$9.67
Fair Value Price
$2.55
Market Cap
$1.16B
52 Week Low
$9.22
52 Week High
$14.63
P/E
-19.73x
P/B
2.19x
P/S
5.5x
PEG
N/A
Dividend Yield
N/A
Revenue
$294.62M
Earnings
-$60.07M
Gross Margin
82.3%
Operating Margin
-16.54%
Profit Margin
-20.4%
Debt to Equity
0.78
Operating Cash Flow
$64M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DVAX Overview
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DVAX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
C
DVAX
Ranked#33 of 61
Ranked#33 of 61
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $24.00 | A | |
| $4.71 | A | |
| $7.60 | A |
Be the first to know about important DVAX news, forecast changes, insider trades & much more!
DVAX News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DVAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DVAX ($9.67) is overvalued by 279.45% relative to our estimate of its Fair Value price of $2.55 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DVAX ($9.67) is not significantly undervalued (279.45%) relative to our estimate of its Fair Value price of $2.55 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DVAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DVAX due diligence checks available for Premium users.
Valuation
DVAX fair value
Fair Value of DVAX stock based on Discounted Cash Flow (DCF)
Price
$9.67
Fair Value
$2.55
Overvalued by
279.45%
DVAX ($9.67) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DVAX ($9.67) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DVAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DVAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-19.73x
Industry
1.77x
Market
25.95x
DVAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.19x
Industry
2.2x
DVAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DVAX's financial health
Profit margin
Revenue
$68.2M
Net Income
-$96.1M
Profit Margin
-141%
DVAX's Earnings (EBIT) of -$48.73M... subscribe to Premium to read more.
Interest Coverage Financials
DVAX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$945.9M
Liabilities
$415.0M
Debt to equity
0.78
DVAX's short-term assets ($815.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DVAX's short-term assets ($815.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DVAX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DVAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.6M
Investing
$6.9M
Financing
-$31.9M
DVAX's operating cash flow ($63.55M)... subscribe to Premium to read more.
Debt Coverage Financials
DVAX vs Pharmaceutical Stocks
Dynavax Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.